![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Renal and Bone Outcomes Among HIV-Infected Patients Exposed to EFV+TDF/FTC Compared to Other TDF-Containing Antiretroviral Regimens:
Findings From the Veterans Health Administration
|
|
|
Reported by Jules Levin
IDWeek 2016 Oct 26-30 New Orleans  
J LaFleur,1,2 S Esker,3 A Bress,2,4 J Crook,2,5 H Nyman,1,2 R Bedimo,6,7 P Tebas,8 L Rosenblatt3
1Department of Pharmacotherapy, University of Utah, Salt Lake City, UT, USA; 2Salt Lake City VA Health Care System, Salt Lake City, UT, USA; 3Bristol-Myers Squibb Company, Princeton, NJ, USA; 4Division of Population Health Sciences, University of Utah, Salt Lake City, UT, USA; 5Division of Epidemiology, University of Utah, Salt Lake City, UT, USA;
6VA North Texas Health Care System, Dallas, TX, USA; 7University of Texas Southwestern Medical Center, Dallas, TX, USA; 8Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
![HIV1](../images/110716/110716-2/HIV1.gif)
![HIV2](../images/110716/110716-2/HIV2.gif)
![HIV3](../images/110716/110716-2/HIV3.gif)
![HIV4](../images/110716/110716-2/HIV4.gif)
![HIV5](../images/110716/110716-2/HIV5.gif)
![HIV6](../images/110716/110716-2/HIV6.gif)
![HIV7](../images/110716/110716-2/HIV7.gif)
![HIV8](../images/110716/110716-2/HIV8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|